Johnson & Johnson MedTech (NYSE: JNJ) today announced the full commercial release of its NuVision Nav ultrasound catheter.
CardioFocus Announces Late-Breaking Data at AF Symposium 2026 and Expands Pulsed Field Ablation Clinical Programs ...
First regulatory approval for the first-of-its-kind, fully-integrated PFA system with a simple and reproducible workflow Integrated with the world's leading CARTO™ 3D cardiac mapping system for the ...
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium
Both the inspIRE and admIRE studies were conducted using the Biosense Webster VARIPULSE™ Platform, consisting of the VARIPULSE™ Catheter – a fully integrated variable-loop multielectrode catheter; the ...
HAYWARD, Calif., April 23, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. Integrated with the world's leading CARTO™ 3D Cardiac Mapping System for the ...
The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ 3 Electro-anatomical Mapping System, driving efficiency, reproducibility ...
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium
IRVINE, Calif., Feb. 2, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, announced 12-month results from the company ...
IRVINE, Calif., Jan. 9, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, i today announced approval from the Japanese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results